Analysis of the effect of mobosetinib (Anvili) in the treatment of EGFR exon 20 insertion mutations

Mobocertinib is a new oral targeted drug that specifically targets the EGFR exon20NSCLC) with an>insertion mutation (Exon20ins). Such mutations are relatively rare in NSCLC, but patients who are resistant to traditional EGFR tyrosine kinase inhibitors (TKIs) often lack effective targeted treatment options. Mobosetinib selectively inhibits the tyrosine kinase activity of EGFR exon 20 insertion mutant protein, thereby blocking downstream signaling pathways, inhibiting tumor cell proliferation and inducing apoptosis, providing new treatment hope for such patients.

Clinical studies have shown that mobosetinib has certain efficacy in patients with EGFRexon20insertion mutationsNSCLC. Key Phase II clinical trial data show that in patients with advanced NSCLC who have previously received chemotherapy, the objective response rate (ORR) of mobosetinib is approximately 28% to 32%, the disease control rate (DCR) can reach 70% or more, and the median progression-free survival (PFS) is about 7 months. This shows that mobosetinib can significantly delay disease progression and buy time for long-term survival in this type of refractory patients.

In terms of efficacy, mobosetinib has advantages over traditional chemotherapy regimens. The ORR of traditional platinum-based chemotherapy in patients with EGFR exon 20 insertion mutations is generally only 10%-15% and is accompanied by more systemic toxic and side effects. In contrast, mobosetinib can both improve the response rate and can be administered orally to improve patients' quality of life. However, some patients may develop drug resistance or disease progression, so it is still necessary to combine clinical monitoring and imaging evaluation to adjust the treatment plan in a timely manner.

The side effects of mobosetinib are mostly controllable, including diarrhea, rash, nausea, stomatitis, and mild elevation of serum creatinine. Most adverse reactions are grade 1-2 and can be managed with dose adjustment or supportive care. For elderly patients or patients with underlying diseases, doctors usually conduct a full assessment before treatment and strengthen follow-up during the treatment process to ensure the efficacy while minimizing the impact of adverse reactions. Overall, mobosetinib provides an important targeted treatment option for patients with EGFR exon 20 insertion mutations and is currently one of the few effective innovative drugs in this field.

Reference link:https://www.drugs.com